Next-Gen Genetic Medicine - MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with four late-stage clinical programs targeting the eye, Parkinson's disease, and xerostomia. The company uses innovative capsid, promoter, and translational control technologies to develop potent viral vectors, supported by end-to-end in-house GMP manufacturing. MeiraGTx has also developed a proprietary riboswitch platform enabling oral small molecule control of in vivo gene expression for metabolic and oncology applications.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Aug 2024
Jun 2018
Jun 2017
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
